OCT 10, 2019 01:30 PM PDT

Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Assistant Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute
    Biography
      Dr. Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School and completed residency in internal medicine and fellowship in hematology/oncology at Duke University. She is currently an Assistant Professor within the Division of Medical Oncology at Duke, specializing in genitourinary (GU) malignancies. She actively leads both clinical and translational research studies in the GU oncology and Phase I groups. She is the overall study chair for the phase 3 PDIGREE trial for metastatic renal cell carcinoma in the Alliance cooperative group and also serves as PI for several investigator-initiated trials in prostate and bladder cancer at Duke. She is committed to improving novel therapies and biomarkers for patients with GU malignancies.

    Abstract:

    Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In this setting, many resistance mechanisms exist, driven both through the androgen receptor (AR) and independent of AR. In this resistant setting, more molecular biomarkers are now available to guide treatment selection. Of these, the AR-v7 splice variant of the androgen receptor can guide selection for chemotherapy based on the PROPHECY study. Furthermore, patients with mutations in DNA damage repair genes (particularly BRCA2, CDK12, BRCA1, CHEK2, and ATM) are especially susceptible to PARP inhibitors. PROfound, a recent phase 3 trial of mCRPC patients previously treated with docetaxel randomized to olaparib vs secondary hormonal inhibitors, showed improved progression free survival and ORR for olaparib. Patients with CDK12 loss and microsatellite instability also respond well to pembrolizumab, an immune checkpoint inhibitor. Therefore, given these targeted treatments outside of standard of care options, there is more impetus to perform genomic testing to evaluate for molecular biomarkers for mCRPC patients. This talk highlights these molecular alterations and treatment options in mCRPC.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    Loading Comments...
    Show Resources